modelB05XA09
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | SodiumPhosphate | |
| ATC code: | B05XA09 | route: | oral |
| compartments: | 1 | |
| dosage: | 45 | mg |
| volume of distribution: | 0.3 | L |
| clearance: | 100 | mL/min |
| other parameters in model implementation | ||
Sodium phosphate is an inorganic phosphate salt used primarily as a laxative and bowel cleanser prior to colonoscopy and other medical procedures. It acts as an osmotic agent, drawing water into the intestines to induce bowel movement. Sodium phosphate is approved for use in many countries but oral formulations have some safety warnings due to risk of acute phosphate nephropathy.
Pharmacokinetics
Estimated pharmacokinetic parameters in healthy adults, as published human PK data for sodium phosphate is scarce. Estimates below are based on typical properties of inorganic phosphate pharmacokinetics.
References
Wen, J, et al., & Gonzalez, D (2024). Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity. Journal of clinical pharmacology 64(12) 1491–1504. DOI:10.1002/jcph.6108 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39120865
Hoy, SM, et al., & Wagstaff, AJ (2009). Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 69(1) 123–136. DOI:10.2165/00003495-200969010-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19192941
Sampathkumar, K (2009). Niacin and analogs for phosphate control in dialysis--perspective from a developing country. International urology and nephrology 41(4) 913–918. DOI:10.1007/s11255-008-9497-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19037739
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)